Tuesday, June 20, 2017 8:11:42 AM
LPCN - 4.02 Pre-market at 5.17/5.20
Lipocine Files 8K - Other Events >LPCN
On June 19, 2017 , Lipocine Inc. issued a press release announcing topline results from the Dosing Validation study and the Dosing Flexibility study for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1535955/ 000114420417033029/v469221_8k.htm
Lipocine Files 8K - Other Events >LPCN
On June 19, 2017 , Lipocine Inc. issued a press release announcing topline results from the Dosing Validation study and the Dosing Flexibility study for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1535955/ 000114420417033029/v469221_8k.htm
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
